Astellas Pharma Inc.

ALPMFOTCHealthcare● Active

$14.48

+$0.28(+1.99%)

Market Cap$25.9B

P/E Ratio—

52W High$17.85

52W Low$9.34

Avg Volume2K

Open$13.25

Beta0.07

Free Cash Flow Financials Revenue

Astellas Pharma Inc. (ALPMF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ALPMF · free cash flow · updated Jun 8, 2026

Core FCF metrics

ALPMF · FCF · TTM · margin & CAGR

Free cash flow was $511.73B for FY2026 (fiscal year ending 2026-03-31), up 273.0% year-over-year The FCF margin was 23.8%. Five-year CAGR stands at +17.4%.

FY2026 Free Cash Flow$511.73B▲ +273.0% YoY

Trailing 12M (TTM)$511.84Btrailing 4 quarters sum

FCF Margin23.8%$511.73B ÷ revenue

3-Year CAGR+28.9%FY2023 → FY2026

5-Year CAGR+17.4%FY2021 → FY2026

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ALPMF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2026Latest$569.82B(58.09B)$511.73B▲ +273.0%23.8%

FY2025$194.51B(57.33B)$137.18B▲ +52.5%7.2%

FY2024$172.47B(82.50B)$89.98B▼ 62.4%5.6%

FY2023$327.77B(88.54B)$239.23B▲ +32.2%15.8%

FY2022$257.44B(76.45B)$181.00B▼ 21.1%14.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ALPMF · P/FCF · FCF yield · FCF per share

Astellas Pharma Inc. (ALPMF) trades at a FCF yield of 13.21% and a price-to-free-cash-flow ratio of 0.1x. FCF per share stands at $285.77, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

13.21%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$285.77

TTM FCF ÷ Shares Outstanding

Price / FCF

x0.1

Share Price ÷ FCF per Share

EV / FCF (TTM)

x8.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2026 · 2026-03-31

Cash flow statement summary

ALPMF · cash flow statement · operating / investing / financing

For FY2026, Astellas Pharma Inc. generated $569.82B in operating cash flow and spent 58.09B in capital expenditures, yielding $511.73B in free cash flow.

Operating Activities

+$569.82B

Cash from core business operations

2026-03-31

Investing Activities

−$73.24B

CapEx, acquisitions & investments

2026-03-31

Financing Activities

−$407.33B

Buybacks, dividends & debt

2026-03-31

FCF FormulaOperating CF ($569.82B) − |CapEx| (58.09B) = FCF ($511.73B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ALPMF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Astellas Pharma Inc.YOU

ALPMF

$511.73B+273.0%23.8%

100%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Astellas Pharma Inc. (ALPMF) reported free cash flow of $511.73B for FY2026 (fiscal year ending 2026-03-31), up 273.0% year-over-year. The FCF margin was 23.8%.

Based on available data, Astellas Pharma Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $511.73B in FY2026. The 5-year CAGR stands at +17.4%.

Astellas Pharma Inc.'s FCF yield is 13.21% and price-to-FCF ratio is 0.1x for FY2026, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ALPMF free cash flow · 8 questions

Astellas Pharma Inc. free cash flow was $511.73B for FY2026, up 273.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $511.84B.

ALPMF free cash flowALPMF FCFALPMF FCF 2026ALPMF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Astellas Pharma Inc. · Astellas Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026